-Advertisement-
-Advertisement-
Neurology

Promising ALS treatment fails to show efficacy in Phase 3 clinical trial
The Phase 3 clinical trial evaluating the terminal complement C5 inhibitor ravulizumab for the treatment of amyotrophic lateral sclerosis (ALS) did not show significant efficacy in slowing the functional decline of participants with ALS. Despite high hopes, the study concluded that ravulizumab did not demonstrate a meaningful difference compared to...
Read More-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement-

Stay Connected! Join Our Newsletter
Contact
Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809
+908-505-8899
[email protected]
© 2023 Med Journal 360™ is a trademark of International Healthcare Media, LLC. All rights Reserved